Intravitreal corticosteroids for diabetic macular edema: a network meta-analysis of randomized controlled trials
Open Access
- 11 October 2021
- journal article
- research article
- Published by Springer Nature in Eye and Vision
- Vol. 8 (1) , 1-13
Abstract
Background: To evaluate the efficacy and safety of different intravitreal corticosteroids for treating diabetic macular edema (DME). Methods: Four databases were systematically searched for randomized controlled trials comparing different intravitreal corticosteroids for treating DME. The primary outcome was the change in best-corrected visual acuity (BCVA) within 6 months after the first injection (short-term BCVA). Secondary outcomes were the change in BCVA over 1 year (long-term BCVA) and changes in central macular thickness (CMT) and intraocular pressure (IOP) within 6 months after the first injection. Network meta-analysis was performed to aggregate the results from the individual studies. Results: Nineteen trials involving 2839 eyes were included. Intravitreal triamcinolone acetonide (TA) injections (≥ 8 mg and 4–8 mg), fluocinolone acetonide (FA) implants (0.5 µg/day) and dexamethasone (DEX) implants (700 µg) improved short-term BCVA (mean changes in logMAR [95% confidence interval] − 0.27 [− 0.40, − 0.15]; − 0.12 [− 0.18, − 0.06]; − 0.10 [− 0.21, − 0.01]; and − 0.06 [− 0.11, − 0.01]). Intravitreal TA injections (4 mg, multiple times), FA implants (0.5 µg/day and 0.2 µg/day), and DEX implants (350 µg) improved long-term BCVA (mean changes in logMAR [95% confidence interval] − 0.11 [− 0.21, − 0.02]; − 0.09 [− 0.15, − 0.03]; − 0.09 [− 0.14, − 0.02]; and − 0.04 [− 0.07, − 0.01]). All intravitreal corticosteroids reduced CMT, and different dosages of TA did not show significant differences in increasing IOP. Conclusions: Intravitreal corticosteroids effectively improved BCVA in DME patients, with higher dosages showing greater efficacies. TA was not inferior to FA or DEX and may be considered a low-cost alternative choice for DME patients. The long-term efficacy and safety of different corticosteroids deserve further investigation. Trial registration Prospectively registered: PROSPERO, CRD42020219870Keywords
This publication has 65 references indexed in Scilit:
- Evidence Synthesis for Decision Making 2Medical Decision Making, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Sustained Ocular Delivery of Fluocinolone Acetonide by an Intravitreal InsertOphthalmology, 2010
- Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo‐controlled, clinical trialActa Ophthalmologica, 2009
- INTRAVITREAL TRIAMCINOLONE FOR DIABETIC MACULAR EDEMARetina, 2008
- Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Rat RetinasDiabetes, 2008
- A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedemaBritish Journal of Ophthalmology, 2007
- Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6‐month results of a prospective controlled trialActa Ophthalmologica Scandinavica, 2006
- Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema: A Prospective, Randomized StudyJournal of Ocular Pharmacology and Therapeutics, 2006
- Combination of direct and indirect evidence in mixed treatment comparisonsStatistics in Medicine, 2004